Tag: Abbott

Abbott new logo

Late-breaking one-year data show Abbott’s next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke

Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions; data show the device achieved high closure rates of the left atrial appendage (LAA) and a low…

Abbott new logo

Abbott’s TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System

SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar to those used to break up kidney stones, to crack calcium in coronary arteries and restore blood flow The system is designed to bring purposeful innovation to…

Abbott new logo

Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition

For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF App Rising PAP can signal worsening heart failure weeks before patients experience symptoms New capabilities…

Abbott new logo

Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms

Abbott’s TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter to treat complex atrial fibrillation (AFib) cases Strong clinical evidence demonstrates the device’s high rates of safety and effectiveness…

Late-breaking data for Abbott’s TactiFlex™ Duo Ablation Catheter reveal positive outcomes for treating complex AFib cases

Abbott’s TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter to treat complex atrial fibrillation (AFib) cases Twelve-month clinical evidence presented at the European Society of Cardiology Congress 2026 demonstrates the device’s high rates of safety and effectiveness in treating […]

Late-breaking data presentations showcase the safety and efficacy of Abbott’s ablation catheters to treat people with atrial fibrillation

Positive 12-month results from the VOLT-AF IDE Study presented at the AF Symposium and simultaneously published in JACC: Clinical Electrophysiology, reinforce the Volt™ Pulsed Field Ablation (PFA) System’s industry-leading success rate for treating AFib1 New data from the FOCALFLEX CE Mark trial demonstrate the safety and efficacy of the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, to […]

Late-breaking data presentations showcase the safety and efficacy of Abbott’s ablation catheters to treat people with atrial fibrillation

Positive 12-month results from the VOLT-AF IDE Study presented at the AF Symposium and simultaneously published in JACC: Clinical Electrophysiology, reinforce the Volt™ Pulsed Field Ablation (PFA) System’s industry-leading success rate for treating AFib1 New data from the FOCALFLEX CE…

Abbott and AtaCor Medical Collaborate on Advanced Extravascular ICD Technology

Collaboration pairs AtaCor’s investigational extravascular ICD lead with Abbott’s investigational extravascular ICD system to deliver potentially life-saving therapies AtaCor plans to initiate a pivotal Investigational Device Exemption (IDE) clinical trial in 2026 to evaluate the investigational extravascular implantable cardioverter defibrillator (EV-ICD) system This initiative furthers Abbott’s leadership in advancing next-generation […]